FDA Acknowledgment Letter to Athyna Pharma

The FDA, through its Center for Drug Evaluation and Research (CDER), has issued an acknowledgment letter to Athyna Pharma, LLC, dated March 13, 2026. This letter serves as confirmation that the FDA has received a submission from the company, as indicated by the posting on regulations.gov.

This document is a routine administrative notice. It does not impose new obligations or require specific actions from regulated entities beyond standard submission procedures. Compliance officers should note this as a confirmation of receipt for Athyna Pharma's filing, but no immediate compliance actions are mandated by this notice itself.